Amgen Inc. (NASDAQ:AMGN) Shares Sold by Good Life Advisors LLC

Good Life Advisors LLC trimmed its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 8.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,429 shares of the medical research company’s stock after selling 126 shares during the period. Good Life Advisors LLC’s holdings in Amgen were worth $412,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of AMGN. Fuller & Thaler Asset Management Inc. raised its stake in shares of Amgen by 1.7% during the third quarter. Fuller & Thaler Asset Management Inc. now owns 11,658 shares of the medical research company’s stock valued at $3,133,000 after purchasing an additional 193 shares during the period. Diversified Trust Co raised its stake in shares of Amgen by 76.8% during the fourth quarter. Diversified Trust Co now owns 37,695 shares of the medical research company’s stock valued at $10,857,000 after purchasing an additional 16,376 shares during the period. Nicolet Advisory Services LLC raised its stake in shares of Amgen by 4.4% during the third quarter. Nicolet Advisory Services LLC now owns 2,805 shares of the medical research company’s stock valued at $745,000 after purchasing an additional 117 shares during the period. Platform Technology Partners raised its stake in shares of Amgen by 7.4% during the third quarter. Platform Technology Partners now owns 5,830 shares of the medical research company’s stock valued at $1,567,000 after purchasing an additional 402 shares during the period. Finally, Busey Trust CO raised its stake in shares of Amgen by 1.2% during the third quarter. Busey Trust CO now owns 76,703 shares of the medical research company’s stock valued at $20,615,000 after purchasing an additional 894 shares during the period. 76.50% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on AMGN shares. Leerink Partnrs lowered shares of Amgen from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 7th. StockNews.com lowered shares of Amgen from a “buy” rating to a “hold” rating in a research note on Thursday. Oppenheimer restated an “outperform” rating and issued a $350.00 price target on shares of Amgen in a research note on Thursday, February 1st. Daiwa Capital Markets upgraded shares of Amgen from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $264.00 to $320.00 in a research note on Thursday, December 21st. Finally, The Goldman Sachs Group lifted their price target on shares of Amgen from $313.00 to $350.00 and gave the stock a “buy” rating in a research note on Wednesday, February 7th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, Amgen currently has an average rating of “Hold” and an average target price of $295.30.

Amgen Stock Performance

Shares of AMGN opened at $284.32 on Friday. The company has a market cap of $152.37 billion, a price-to-earnings ratio of 22.76, a price-to-earnings-growth ratio of 2.66 and a beta of 0.58. The firm has a fifty day moving average of $290.09 and a 200-day moving average of $280.70. Amgen Inc. has a 1 year low of $211.71 and a 1 year high of $329.72. The company has a debt-to-equity ratio of 10.14, a quick ratio of 1.13 and a current ratio of 1.65.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 earnings per share for the quarter, topping the consensus estimate of $4.66 by $0.05. The business had revenue of $8.20 billion during the quarter, compared to the consensus estimate of $8.13 billion. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The company’s quarterly revenue was up 19.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $4.09 earnings per share. As a group, equities analysts anticipate that Amgen Inc. will post 19.49 earnings per share for the current year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be issued a $2.25 dividend. This represents a $9.00 annualized dividend and a yield of 3.17%. The ex-dividend date of this dividend is Thursday, May 16th. Amgen’s payout ratio is currently 72.06%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.